-
Mashup Score: 2My ‘Other Birthday’ is Coming Up After Cancer - 21 hour(s) ago
What it’s like having a “second birthday” after receiving a bone marrow transplant for my AML.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet
-
Mashup Score: 0Novel Duplex Sequencing Assay Improves Detection of MRD in AML | Blood Cancers Today - 24 hour(s) ago
The novel DuplexSeq AML-XP next-generation sequencing assay was highly accurate for detecting MRD in AML.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 1Acute Myeloid Leukemia | Blood Cancers Today - 3 day(s) ago
Acute myeloid leukemia (AML), the most common acute leukemia in adults, can occur when myeloid cells form abnormal myeloblast instead of developing into normal mature blood cells.
Source: bloodcancerstoday.comCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 5Novel AML Therapy, Pivekimab Sunirine, Shows Promising Anticancer Activity | Blood Cancers Today - 13 day(s) ago
Monotherapy with pivekimab sunirine demonstrated activity in patients with relapsed or refractory CD123-positive AML.
Source: bloodcancerstoday.comCategories: General Medicine News, Hematologists1Tweet-
The novel therapy pivekimab sunirine demonstrated promising anticancer activity in patients with relapsed or refractory CD123-positive #AML, according to a study led by @Daver_Leukemia, of @MDAndersonNews, and published in @TheLancetOncol. 📰 Learn more: https://t.co/e71I6SFHp6 https://t.co/NKobx4uGLw
-
-
Mashup Score: 4ASTX727 Plus Venetoclax Is a Safe Regimen in Older Patients With AML | Blood Cancers Today - 16 day(s) ago
The ORR was 64% in the frontline cohort and 46% in the relapsed or refractory cohort.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 5Novel AML Therapy, Pivekimab Sunirine, Shows Promising Anticancer Activity | Blood Cancers Today - 22 day(s) ago
Monotherapy with pivekimab sunirine demonstrated activity in patients with relapsed or refractory CD123-positive AML.
Source: bloodcancerstoday.comCategories: General Medicine News, Hematologists1Tweet-
The novel therapy pivekimab sunirine demonstrated promising anticancer activity in patients with relapsed or refractory CD123-positive #AML, according to a study led by @Daver_Leukemia, of @MDAndersonNews, and published in @TheLancetOncol. 📰 Learn more: https://t.co/e71I6SFHp6 https://t.co/NKobx4uGLw
-
-
Mashup Score: 6Is Gilteritinib Effective as Post-Transplant Maintenance in Patients With FLT3-ITD-Mutated AML? | Blood Cancers Today - 23 day(s) ago
These prospective results establish FLT3-ITD mutations as essential markers of MRD, the authors wrote.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 6Mims Expands on the Evaluation of Emavusertib in the TakeAim Leukemia Trial of AML and MDS - 1 month(s) ago
Dr Mims discusses the utility of emavusertib in acute myeloid leukemia and myelodysplastic syndrome and the rationale for the TakeAim Leukemia trial.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Erik Kimble, MD, Wins Underrepresented Minority Fellowship Award | Blood Cancers Today - 2 month(s) ago
The award grants $100,000 to a postdoctoral or early-career oncology researcher from a racial or ethnic minority group underrepresented in the scientific workforce.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 12Peptide-scFv antigen recognition domains effectively confer CAR T cell multiantigen specificity - PubMed - 2 month(s) ago
The emergence of immune escape is a significant roadblock to developing effective chimeric antigen receptor (CAR) T cell therapies against hematological malignancies, including acute myeloid leukemia (AML). Here, we demonstrate feasibility of targeting two antigens simultaneously by combining a GRP7 …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
After receiving a bone marrow transplant for her #AML in 2020, CURE® blogger Mary looks forward to celebrating this day — what she considers her “second kind of birthday.” Read Mary’s blog here: https://t.co/P5hDWUEqjQ https://t.co/GiAN98kNyY